Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Director comp.
Credit agrmnt [a]
Acq. announced
Consulting agrmnt
Quarterly results
Horizon Therapeutics Public Ltd Co (HZNP) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/17/2014 8-K Acquisition/merger/asset purchase announced
Docs: "Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID ® 2% from Nuvo Research Inc. — Acquisition Bolsters Primary Care Product Portfolio — — Horizon to Host Conference Call/Webcast at 8:00 a.m. EST — DUBLIN, IRELAND — - October 17, 2014 - Horizon Pharma plc , a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today the acquisition of the U.S. rights to PENNSAID ® 2% w/w from Nuvo Research Inc. for a one-time payment of $45 million in cash. PENNSAID 2% is approved in the U.S. for the treatment of the pain of osteoarthritis of the knee. PENNSAID 2% is a second generation version of PENNSAID ® 1.5% w/w . Effective January 1, 2015, PENNSAID 1.5% w/w will no longer be marketed in the U.S. Nuvo will retain it..."
09/19/2014 8-K Director compensation was amended/approved, Acquisition/merger/asset purchase announced, Entered into consulting agreement
Docs: "Memorandum and Articles of Association of Horizon Pharma Public Limited Company",
"First Supplemental Indenture, by and among Horizon Pharma, Inc., Horizon Pharma Public Limited Company and U.S Bank National Association",
"Form of Indemnification Agreement entered into by and between Horizon Pharma Public Limited Company and certain of its directors, officers and employees",
"Form of Indemnification Agreement entered into by and between Horizon Pharma, Inc. and certain directors, officers and employees of Horizon Pharma Public Limited Company",
"Temporary Escrow Agreement, by and among Vidara Therapeutics Holdings LLC, Horizon Pharma, Inc. and Citibank, National Association, as escrow agent",
"Horizon Pharma Public Limited Company Non-Employee Director Compensation Policy",
"Code of Business Conduct and Ethics of Horizon Pharma Public Limited Company",
"Letter from Habif, Arogeti & Wynne LLP",
"Description of Horizon Pharma Public Limited Company Share Capital",
"Registration Rights Agreement, by and among Vidara Therapeutics International plc (now known as Horizon Pharma Public Limited Company), Vidara Therapeutics Holdings LLC and certain shareholders of Vidara Therapeutics International plc"
11/22/2013 8-K Acquisition/merger/asset purchase announced
Docs: "Indenture, by and between Horizon Pharma, Inc. and U.S. Bank National Association",
"Capped Call Confirmation, by and between Horizon Pharma, Inc. and Deutsche Bank AG, London Branch",
"Capped Call Confirmation, by and between Horizon Pharma, Inc. and Société Générale"
11/19/2013 8-K Acquisition/merger/asset purchase announced
Docs: "Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO ® and Provides 2014 Guidance",
"2011 Equity Incentive Plan, as amended, and Form of Option Agreement and Form of Stock Option Grant Notice thereunder",
"Company Disclosure"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy